Travere Q3 U.S. Product Sales Rise 95% as FILSPARI Reaches $200 Million

Travere Therapeutics reported about $220 million in total U.S. net product sales for the third quarter of 2026, an increase of roughly 95% from a year earlier, as FILSPARI demand expanded across IgA nephropathy and the newly approved focal segmental glomerulosclerosis indication. U.S. net sales of FILSPARI accounted for $200 million of the quarterly total, making the rare-kidney-disease therapy the central driver of Travere’s commercial growth.

The San Diego-based biopharmaceutical company, which trades under the ticker TVTX, recorded 1,932 new FILSPARI patient start forms during the quarter, up 120% from the third quarter of 2025. Travere said demand was coming from both new and repeat prescribers, supported by high patient compliance and persistence and a broader prescriber base.

FILSPARI, or sparsentan, is approved in the U.S. to slow kidney-function decline in adults with primary IgA nephropathy, or IgAN, who are at risk of progression. In April 2026, the Food and Drug Administration also approved the drug to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome.

FILSPARI expansion centers on IgAN and FSGS

Travere estimates that more than 100,000 U.S. patients are addressable across the two indications, including more than 70,000 with IgAN and more than 30,000 with FSGS. The company said FILSPARI has reached approximately 10% penetration of that combined market, leaving room for additional adoption. It estimates a U.S. sales opportunity exceeding $3 billion by 2033, including more than $1 billion in IgAN, although those figures remain company projections.

In IgAN, Travere is positioning FILSPARI as a long-term, non-immunosuppressive therapy that can replace historical renin-angiotensin system inhibitor treatment. The company highlighted 2025 KDIGO guidelines that call for earlier diagnosis, lower proteinuria targets and simultaneous treatment in many patients. FILSPARI’s clinical profile includes once-daily oral dosing, streamlined liver monitoring and two-year data comparing the drug with the active comparator irbesartan.

Additional evidence-generation programs are intended to support broader use. In the SPARTAN study of newly diagnosed, treatment-naïve IgAN patients, Travere reported an approximately 77% reduction in proteinuria and stabilization of estimated glomerular filtration rate through week 110, with about 75% of patients achieving complete remission. The SPARX study is evaluating FILSPARI in recurrent IgAN and FSGS after kidney transplantation, with data presentations expected in 2027.

The FSGS launch is using the same field organization, payer relationships, distribution channel and patient-support infrastructure already established for IgAN. Travere said substantial overlap among prescribers allows its commercial team to address both indications. The company is also initiating the SPARLIGHT study to generate evidence in patients of African ancestry with FSGS.

Outside the U.S., Travere has licensed sparsentan rights in multiple territories to CSL Vifor and Chugai Pharmaceutical. FILSPARI has received standard approval in Europe and the U.K. and has launched in Germany, Austria, Switzerland, Luxembourg and the U.K. Chugai has submitted a new drug application for sparsentan in Japan. Travere is eligible for up to $910 million in potential milestone payments under the licensing arrangements, covering both IgAN and FSGS, plus tiered double-digit royalties on global net sales. Through June 2026, it had received $63.5 million in disclosed milestone payments.

Pegtibatinase study remains on track for 2027 data

Travere’s next potential approved medicine is pegtibatinase, an investigational enzyme-replacement therapy for classical homocystinuria, or HCU. The therapy is designed to address the underlying genetic cause of the disease by introducing the cystathionine beta-synthase enzyme into circulation and reducing homocysteine levels.

Enrollment is continuing in the pivotal Phase 3 HARMONY study after the first new patient following the study’s restart was dosed in April 2026. Site activation has been completed, and Travere expects topline efficacy data in the second half of 2027. The study is expected to enroll about 70 patients and compares twice-weekly subcutaneous pegtibatinase with placebo over 24 weeks.

In the earlier Phase 1/2 COMPOSE study, the highest-dose cohort produced a 67.1% mean relative reduction in total homocysteine from baseline, and pegtibatinase was generally well tolerated across the tested doses. The company views the candidate as a potential first disease-modifying therapy for HCU if approved.

Civorebrutinib broadens kidney-disease pipeline

Travere is also developing civorebrutinib, an oral, covalent reversible Bruton tyrosine kinase inhibitor, as a potential platform for immune-mediated rare kidney diseases. Initial development is focused on primary membranous nephropathy, with possible expansion into immune-mediated FSGS, minimal change disease and other indications.

Phase 1b/2a data in primary membranous nephropathy showed an approximately 90% reduction in anti-PLA2R autoantibodies by week 12 in the higher-dose cohort. Proteinuria declined by about 80% in both cohorts by week 36, with the reduction sustained after treatment ended, according to data with a September 2025 cutoff.

Among 31 treated patients, 87.1% experienced a treatment-emergent adverse event and 19.4% had a serious treatment-emergent adverse event. Treatment-related serious events occurred in 12.9%, while two patients discontinued treatment because of adverse events. No deaths were reported. Travere said the study did not identify clinically meaningful events typically associated with BTK inhibitors, including neutropenia, hemorrhage or cardiac arrhythmia.

Cash position supports commercial and clinical programs

Travere ended September with approximately $472 million in cash, cash equivalents and marketable securities. It had about 95 million basic shares outstanding and an estimated diluted share count of roughly 108 million, including outstanding equity awards but excluding convertible notes. The company reported $95 million of convertible notes due in March 2029 and $525 million due in May 2032.

Execution remains subject to several uncertainties. Travere identified risks around the FSGS launch and continued IgAN commercialization, including market acceptance, efficacy and safety perceptions, pricing, reimbursement and competition. Its development programs also face the possibility of enrollment delays, adverse clinical or regulatory outcomes and manufacturing or supply disruptions. Other risks include dependence on contractors, patent and exclusivity issues, potential changes in FDA funding or priorities, tariffs, and the possibility that expected milestone or royalty payments may not be received. The company also cautioned that its cash runway may be shorter than anticipated and that additional financing could be required to complete development of its product candidates.